Introduction {#section5-1176935119870817}
============

Acute myeloid leukemia (AML) is an extremely heterogeneous malignant disorder; in recent years, AML developed so rapidly by affecting children and adults, and hence it has been reported as one of the main causes of death in children.^[@bibr1-1176935119870817][@bibr2-1176935119870817][@bibr3-1176935119870817][@bibr4-1176935119870817]-[@bibr5-1176935119870817]^ It is the most common acute leukemia in adults,^[@bibr6-1176935119870817][@bibr7-1176935119870817]-[@bibr8-1176935119870817]^ with a frequency of more than 20 000 cases per year in the United States alone.^[@bibr6-1176935119870817]^ It is characterized by genetic alterations in hematopoietic ancestor cells that change usual mechanisms of self-replicating.^[@bibr2-1176935119870817],[@bibr9-1176935119870817]^ AML is commonly triggered by mutation in CCAAT/enhancer-binding protein-alpha (*CEBPA*) gene.^[@bibr10-1176935119870817][@bibr11-1176935119870817][@bibr12-1176935119870817][@bibr13-1176935119870817]-[@bibr14-1176935119870817]^ The *CEBPA* is a transcription element that affects immune cell density and diversity.^[@bibr15-1176935119870817],[@bibr16-1176935119870817]^ Most patients with AML who have *CEBPA* alterations simultaneously transport double mutations,^[@bibr17-1176935119870817][@bibr18-1176935119870817]-[@bibr19-1176935119870817]^ nevertheless, different mutations have been reported^[@bibr20-1176935119870817][@bibr21-1176935119870817][@bibr22-1176935119870817][@bibr23-1176935119870817]-[@bibr24-1176935119870817]^; some studies have been reported which claimed some related factors besides *CEBPA* mutation, such as smoking, alcohol, and exposure to solvents and agrochemicals may cause AML,^[@bibr25-1176935119870817][@bibr26-1176935119870817]-[@bibr27-1176935119870817]^ but no evidence of publication bias. Other genes have been reported which cause AML such as *fms-related tyrosine kinase 3* (*FLT3-ITD*) and *nucleophosmin 1* (*NMP1*), which assisted to improve person diagnosis; furthermore, these mutant molecules characterize as a potential target for molecular therapies.^[@bibr6-1176935119870817],[@bibr28-1176935119870817][@bibr29-1176935119870817][@bibr30-1176935119870817]-[@bibr31-1176935119870817]^ Sometimes, patients with chronic lymphocytic leukemia can develop AML,^[@bibr32-1176935119870817]^ whereas in rare cases patients with AML can develop esophageal cancer.^[@bibr33-1176935119870817]^

Stem cell transplantation treatment is related to the result of treatment for patients with cytogenetically usual AML.^[@bibr34-1176935119870817]^ Nevertheless, the advantage of the transplant is exclusive to subcategory of patients with *CEBPA* mutations alone^[@bibr31-1176935119870817],[@bibr34-1176935119870817]^; in spite of this hopeful recent evolution, the outcomes of patients with AML remain insufficient, with more than 50% of the patients eventually dying from this devastating disease. The purpose of this study is to classify functional mutations located in the coding region of *CEBPA* gene using in silico analysis.

Disease-causing single nucleotide polymorphisms (SNPs) are frequently found to arise at evolutionarily conserved regions; these have a key role at structural and functional levels of the protein. The capability to calculate whether a particular SNP is deleterious or not is very important for the prognosis of disorder.^[@bibr35-1176935119870817][@bibr36-1176935119870817][@bibr37-1176935119870817][@bibr38-1176935119870817][@bibr39-1176935119870817][@bibr40-1176935119870817][@bibr41-1176935119870817][@bibr42-1176935119870817][@bibr43-1176935119870817][@bibr44-1176935119870817]-[@bibr45-1176935119870817]^ The practice of translational bioinformatics has solid influence on the identification of candidate SNPs and can contribute in pharmacogenomics by identifying high-risk SNP mutation contributing to drug response as well as developing novel therapeutic elements for this deadly disease.^[@bibr46-1176935119870817][@bibr47-1176935119870817][@bibr48-1176935119870817][@bibr49-1176935119870817][@bibr50-1176935119870817][@bibr51-1176935119870817][@bibr52-1176935119870817][@bibr53-1176935119870817]-[@bibr54-1176935119870817]^ This is the first silico analysis in coding and non-coding regions of *CEBPA* gene that prioritized SNPs to be used as diagnostic markers with a special consideration of the large heterogeneity of AML among different populations.

Materials and Methods {#section6-1176935119870817}
=====================

Data mining {#section7-1176935119870817}
-----------

The polymorphic data of *CEBPA* gene were claimed from National Center for Biotechnology Information (NCBI) website (<https://www.ncbi.nlm.nih.gov/>), and the reference sequence of human protein was collected from UniProt^[@bibr55-1176935119870817]^ (<https://www.uniprot.org/>).

Functional analysis {#section8-1176935119870817}
-------------------

### Sorting Intolerant From Tolerant {#section9-1176935119870817}

It is the first in silico functional analysis that calculates whether an amino acid alteration affects protein function or not. Sorting Intolerant From Tolerant (SIFT) scores \< 0.05 are expected to be damaging altered amino acid, otherwise it is considered to be tolerant.^[@bibr56-1176935119870817]^ It is available at <https://sift.bii.a-star.edu.sg/>.

### PolyPhen-2 {#section10-1176935119870817}

It is a trained machine learning to predict whether an amino acid replacement affects protein function and structure or not, by calculating position-specific independent count (PSIC) for each SNP at a time. There are 2 outputs whether probably damaging (values are more frequently 1) and possibly damaging or benign (values range from 0 to 0.95).^[@bibr57-1176935119870817]^ It is available at <http://genetics.bwh.harvard.edu/pph2/>.

### PROVEAN {#section11-1176935119870817}

It is an online in silico functional analysis tool that calculates whether an amino acid replacement has an influence on the organic function of a protein stranded on the alignment-based score. If the PROVEAN score ⩽ --2.5, the protein variant is expected to have a "deleterious" effect, whereas if the PROVEAN score is \>--2.5, the variant is expected to have a "neutral" effect.^[@bibr58-1176935119870817]^ It is available at <http://provean.jcvi.org/index.php>.

### SNAP2 {#section12-1176935119870817}

It is a trained functional analysis tool that differentiates between effect and neutral SNPs by taking various features into validation. SNAP2 got an accuracy of 83%, which has 2 expectations: effect (positive score) or neutral (negative score). It is considered an important and substantial enhancement over other methods. It is available at <https://rostlab.org/services/snap2web/>.

### SNPs&GO {#section13-1176935119870817}

It is a trained machine learning based on the technique to precisely calculate the deleterious associated alterations from protein sequence. SNPs&GO collects in a unique framework information derived from protein sequence, evolutionary information, and function as coded in the Gene Ontology terms and underperforms other available predictive methods (PhD-SNP and PANTHER).^[@bibr59-1176935119870817]^ It is available at <http://snps.biofold.org/snps-and-go/snps-and-go.html>.

### PMut {#section14-1176935119870817}

It is a web-based tool for the explanation of SNP alternates on proteins, which allows the rapid and precise calculation (80%) of the compulsive features of each SNP grounded on the practice of neural networks.^[@bibr60-1176935119870817]^ It is accessible at <http://mmb.irbbarcelona.org/PMut>.

Stability analysis {#section15-1176935119870817}
------------------

### I-Mutant 3.0 {#section16-1176935119870817}

I-Mutant is a support vector machine (SVM)-based tool. I-Mutant predicts whether the protein mutation stabilizes or destabilizes the protein structure by calculating free energy change by coupling predictions with the energy-based FOLD-X tool.^[@bibr61-1176935119870817]^ It is available at <http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi>.

### MUpro {#section17-1176935119870817}

It is a structural analysis online tool for the calculation of protein stability variations in arbitrary SNPs. The value of the energy change is expected, and assurance mark between −1 and 1 for evaluating the assurance of the expectation is calculated. A score of \<0 means the mutant decreases the protein stability; conversely, a score of \>0 means the mutant increases the protein stability.^[@bibr62-1176935119870817]^ It is available at <http://mupro.proteomics.ics.uci.edu/>.

3-Dimensional clustering analysis {#section18-1176935119870817}
---------------------------------

### Mutation3D {#section19-1176935119870817}

It is a functional calculation and visualization online tool for investigating the 3-dimensional (3D) plan of amino acid alterations in protein models and structures.^[@bibr63-1176935119870817]^ It is available at <http://mutation3d.org>.

Biophysical validation {#section20-1176935119870817}
----------------------

### Project HOPE {#section21-1176935119870817}

It is a web server to search protein 3D structures by bringing together structural information from several sources such as UniProt database. The main aims for the submissions in Project HOPE are to analyze and confirm the results that we obtained earlier. It is available at <http://www.cmbi.ru.nl/hope>.

Conservational analysis {#section22-1176935119870817}
-----------------------

### BioEdit {#section23-1176935119870817}

It is a software package proposed to stream a distinct program that can run nearly any sequence operation as well as a few basic alignment investigations. It is available for download at <http://www.mbio.ncsu.edu/bioedit/bioedit.html>.

### ConSurf server {#section24-1176935119870817}

It is a web server that offers evolutionary conservation summaries for proteins of known structure in the protein data bank. ConSurf spots the parallel amino acid sequences and runs multialignment methods. The conserved amino acid across species flags its position using specific algorithm.^[@bibr64-1176935119870817]^ It is available at <http://consurf.tau.ac.il/>.

3D structural analysis {#section25-1176935119870817}
----------------------

### RaptorX {#section26-1176935119870817}

The 3D structure of human CEBPA protein is not available in the Protein Data Bank. Hence, RaptorX was used to make a 3D structural model for wild-type CEBPA. RaptorX is a web server predicting structure property of a protein sequence without using any templates.^[@bibr65-1176935119870817]^ It is available at <http://raptorx.uchicago.edu/>.

### UCSF Chimera {#section27-1176935119870817}

It is a visualization analysis program of 3D structure prototype, docking analysis, and so many related analyses. A predicted model was created by RaptorX to visualize and compare the amino acid alterations using UCSF Chimera.^[@bibr66-1176935119870817]^ UCSF Chimera 1.8 is free for download at <http://www.cgl.ucsf.edu/chimera/>.

GeneMANIA {#section28-1176935119870817}
---------

It is a method to know protein function prediction integrating multiple genomics and proteomics data sources to make inferences about the function of unknown proteins.^[@bibr67-1176935119870817]^ It is available at <http://www.genemania.org/>.

Variant Effect Predictor {#section29-1176935119870817}
------------------------

The Ensembl Variant Effect Predictor (VEP) software provides tools and methods for a systematic approach to annotate and aid prioritization of variants in both large-scale sequencing projects and smaller analysis studies.^[@bibr68-1176935119870817]^ It is available at <http://www.ensembl.org/vep>.

PolymiRTS server {#section30-1176935119870817}
----------------

It is a server for investigating functional SNPs in 3′-untranslated region (3′-UTR) of *CEBPA* gene that may change miRNA binding on target sites, resulting in different functional consequences.^[@bibr69-1176935119870817]^ It is available at <http://compbio.uthsc.edu/miRSNP/>.

Results {#section31-1176935119870817}
=======

The total number of SNPs in different regions of *CEBPA* gene was retrieved from NCBI. The distribution of non-synonymous single nucleotide polymorphisms (nsSNPs) in coding and non-coding regions of *CEBPA* gene contained 248 nsSNPs, with 350 SNPs in the 3′-UTR and 11 in the 5′-untranslated region (5′-UTR; [Figure 1](#fig1-1176935119870817){ref-type="fig"}).

![The distribution of SNPs in coding and in non-coding regions of *CEBPA* gene. SNPs indicates single nucleotide polymorphisms.](10.1177_1176935119870817-fig1){#fig1-1176935119870817}

A total of 248 missense mutations were retrieved from the database of single nucleotide polymorphism (dbSNP)/NCBI database, and these SNPs were submitted into different functional analysis tools such as SIFT, polymorphism phenotyping v2 (PolyPhen-2), PROVEAN, and SNAP2, respectively. Sorting Intolerant From Tolerant server predicted 28 deleterious SNPs, PolyPhen-2 predicted 85 damaging SNPs (29 were possibly damaging and 56 were probably damaging to protein), PROVEAN represented 34 deleterious SNPs, whereas in SNAP2 we filtered the triple-positive deleterious SNPs from the previous 3 analysis tools, out of 53 SNPs there were 19 predicted deleterious SNPs by SNAP2. [Table 1](#table1-1176935119870817){ref-type="table"} represents the Quad-positive of deleterious SNPs after filtrations, the number decreased rapidly to 19 SNPs, after submitting them into SNPs&GO and PhD-SNP, PMut and PANTHER, respectively, to run more investigation on these SNPs and their effect on the functional level. The triple positive in the 3 tools was 5 disease-associated SNPs ([Table 2](#table2-1176935119870817){ref-type="table"}). Finally, we submitted them to I-mutant 3.0 and MUpro, respectively, to investigate their effect on structural level. The 2 online tools revealed that all 5 mutations predicted a dramatic decrease in the protein stability, except for 2 SNPs (N292T and D63N) that were predicted by I-Mutant to increase the stability of the protein ([Table 3](#table3-1176935119870817){ref-type="table"}).

###### 

Affect or damaging nsSNPs associated predicted by various software.

![](10.1177_1176935119870817-table1)

  dbSNP rs\#     SUB     SIFT prediction   Score   PolyPhen prediction   Score   PROVEAN prediction   Score    SNAP2 prediction   Score
  -------------- ------- ----------------- ------- --------------------- ------- -------------------- -------- ------------------ -------
  rs1358286265   G355V   AFFECT            0       Damaging              1       Deleterious          −7.083   Effect             48
  rs1402033817   G355S   AFFECT            0       Damaging              1       Deleterious          −4.501   Effect             47
  rs1439202716   R343C   AFFECT            0       Damaging              1       Deleterious          −6.702   Effect             43
  rs1455027551   R339W   AFFECT            0       Damaging              1       Deleterious          −7.798   Effect             74
  rs758726582    R333C   AFFECT            0       Damaging              1       Deleterious          −7.409   Effect             14
  rs1422138876   V328G   AFFECT            0       Damaging              1       Deleterious          −6.823   Effect             51
  rs1306818311   R327W   AFFECT            0       Damaging              1       Deleterious          −6.468   Effect             47
  rs781549846    R325C   AFFECT            0       Damaging              1       Deleterious          −6.324   Effect             19
  rs1013241741   S299C   AFFECT            0       Damaging              1       Deleterious          −4.866   Effect             23
  rs1391793930   K298R   AFFECT            0       Damaging              1       Deleterious          −2.924   Effect             31
  rs1392203731   K298Q   AFFECT            0       Damaging              1       Deleterious          −3.899   Effect             34
  rs776590829    N292T   AFFECT            0       Damaging              1       Deleterious          −5.788   Effect             35
  --             N292S   AFFECT            0       Damaging              1       Deleterious          −4.907   Effect             29
  rs1064794962   R288P   AFFECT            0       Damaging              1       Deleterious          −6.636   Effect             66
  rs376856647    E284D   AFFECT            0       Damaging              1       Deleterious          −2.694   Effect             44
  rs1196766447   E284A   AFFECT            0       Damaging              1       Deleterious          −5.588   Effect             18
  rs1352573347   P233H   AFFECT            0       Damaging              1       Deleterious          −3.924   Effect             37
  rs1267025311   R156W   AFFECT            0       Damaging              1       Deleterious          −2.983   Effect             71
  rs1452063514   D63N    AFFECT            0       Damaging              1       Deleterious          −2.992   Effect             72

Abbreviations: dbSNP, database of single nucleotide polymorphism; nsSNPs, non-synonymous single nucleotide polymorphisms; SIFT, Sorting Intolerant From Tolerant; SUB, substitution.

###### 

Pathogenic nsSNPs associated variations predicted by various software.

![](10.1177_1176935119870817-table2)

  SUB     SNPs&GO prediction   RI   Probability   PANTHER prediction   RI   Probability   PhD-SNP prediction   RI   Probability   PMut prediction   Probability
  ------- -------------------- ---- ------------- -------------------- ---- ------------- -------------------- ---- ------------- ----------------- -------------
  R339W   Disease              1    .539          Disease              9    .949          Disease              2    .615          Disease           .85 (91%)
  N292T   Disease              5    .723          Disease              10   .985          Disease              4    .749          Disease           .85 (91%)
  N292S   Disease              5    .751          Disease              10   .98           Disease              5    .767          Disease           .85 (91%)
  R288P   Disease              4    .704          Disease              7    .86           Disease              7    .872          Disease           .85 (91%)
  D63N    Disease              4    .717          Disease              9    .94           Disease              4    .697          Disease           .67 (85%)

Abbreviations: nsSNPs, non-synonymous single nucleotide polymorphisms; RI, reliability index; SUB, substitution.

###### 

Structural investigation calculated using I-Mutant 3.0 and MUpro.

![](10.1177_1176935119870817-table3)

  dbSNP rs\#     SUB     I-mutant prediction   RI   DDG value prediction   MUpro prediction   Score
  -------------- ------- --------------------- ---- ---------------------- ------------------ ----------
  rs1455027551   R339W   Decrease              3    −0.21                  Decrease           −0.24675
  rs776590829    N292T   Increase              2    −0.35                  Decrease           −1.48124
  --             N292S   Decrease              6    −0.73                  Decrease           −1.46979
  rs1064794962   R288P   Decrease              5    −0.73                  Decrease           −0.66005
  rs1452063514   D63N    Increase              1    −0.2                   Decrease           −1.22302

Abbreviations: dbSNP, database of single nucleotide polymorphism; RI, reliability index; SUB, substitution.

DDG value: free energy changes value.

Single nucleotide polymorphisms in 3′-UTR of *CEBPA* gene were submitted as batch to PolymiRTS server. The result shows that among 350 SNPs in the 3′-UTR of *CEBPA* gene, about 11 SNPs were predicted, namely, rs116528776, rs113670631, rs34017519, rs146104564, rs187516157, rs2376497, rs192371350, rs1049969, rs41367646, rs184965384, and rs187751931; among these 11 SNPs, 65 alleles disrupted a conserved miRNA site and 22 derived alleles created a new site of miRNA ([Table 6](#table6-1176935119870817){ref-type="table"}).

Discussion {#section32-1176935119870817}
==========

In vitro mutagenesis, functional and characterization studies, is an unwieldy task regarding workload, time, and fees. For these reasons, bioinformatics analysis is an appropriate, rapid, low-cost, and dependable approach to enhance our understanding of how mutations could disturb the protein structure and function.^[@bibr53-1176935119870817],[@bibr54-1176935119870817]^ Disease-causing SNPs are commonly found to arise at evolutionarily conserved regions. Those have a key role at structural and functional levels of the protein^[@bibr36-1176935119870817],[@bibr38-1176935119870817]^; therefore, our focus was dedicated to the coding region, which unmasked 5 mutations in *CEBPA* gene using different sequence and structure-based algorithms ([Figure 2](#fig2-1176935119870817){ref-type="fig"}). The SNPs that have been found in this study could be used in prognostics of disease, because identification of *CEBPA* status in AML has a major clinical importance, allowing relapse risk to be stratified properly for post-remission treatment.^[@bibr70-1176935119870817],[@bibr71-1176935119870817]^

![Descriptive workflow of softwares used in SNP analysis. SNP indicates single nucleotide polymorphism.](10.1177_1176935119870817-fig2){#fig2-1176935119870817}

All these SNPs (D63N, R288P, N292T, N292S, and R339W) were retrieved from the dbSNPs/NCBI database as untested and all were found to be pathogenic mutations.

At the functional level analysis, our results showed that all these nsSNP substitutions (D63N, R288P, N292T, N292S, and R339W) were classified as highly pathogenic mutations ([Table 1](#table1-1176935119870817){ref-type="table"}). The analysis of different SNPs on the protein structure can disturb interactions with other molecules, MUpro results showed a decrease in stability for all these SNPs (D63N, R288P, N292T, N292S, and R339W), whereas I-Mutant results showed a decrease in stability for these SNPs (R288P, N292S, and R339W), thus suggesting that these mutations could directly or indirectly destabilize the amino acid interactions triggering functional deviations of protein to some point.

*CEBPA* offers information for building a protein termed CCAAT enhancer-binding protein alpha. It's a transcription factor (TF) and its performance is a malignant suppressor, which means it is complicated in cellular mechanisms and could help to prevent the cells from developing and dividing too swiftly or in an uncontrolled mode and that is the principle of cancer.^[@bibr24-1176935119870817],[@bibr72-1176935119870817]^ We also achieved analysis by Mutation3D server, all SNPs in red (R288P, N292S, and N292T) are clustered mutation, significantly, such mutation clusters are commonly associated with human cancers,^[@bibr73-1176935119870817]^ whereas SNPs in blue (R339W) and gray (D63N) are covered and uncovered mutations, respectively ([Figure 3](#fig3-1176935119870817){ref-type="fig"}).

![Structural simulations for mutant residues in CEBPA protein, demonstrated by Mutation3D.](10.1177_1176935119870817-fig3){#fig3-1176935119870817}

Project HOPE server was used to submit the most damaging SNPs (R288P): interestingly, proline interrupts an α-helix when not positioned at 1 of the first 3 positions of that helix. If this happened, a major impact on the protein structure could occur ([Figure 4](#fig4-1176935119870817){ref-type="fig"}). In this study, we also observed that only 1 SNP (D63N), the residue predicted to be mutated, is evolutionarily conserved across species, and this may increase the possibility of altered transcriptional and cell cycle regulation ([Figure 5](#fig5-1176935119870817){ref-type="fig"}).

![The mutant residue located in an α-helix.](10.1177_1176935119870817-fig4){#fig4-1176935119870817}

![Alignments of 8 amino acid sequences of CEBPA representing that the residues predicted to be mutated are evolutionarily conserved across species. Sequences alignment was done by BioEdit (v7.2.5).](10.1177_1176935119870817-fig5){#fig5-1176935119870817}

The 3D protein structure analysis enables mapping of amino acid substitutions and, therefore, RaptorX was used to make a 3D structure model for CEBPA protein ([Figure 6](#fig6-1176935119870817){ref-type="fig"}) to support and match the results acquired from different computational tools, UCSF Chimera serves this purpose ([Figures 7](#fig7-1176935119870817){ref-type="fig"} to [11](#fig11-1176935119870817){ref-type="fig"}), show the differences between native and mutant amino acids, in the green and red boxes the schematic structures of the native amino acids (in the left side), and the mutant ones (in the right side). The backbone, which is the same for each amino acid, is colored red and the side chain, unique for each amino acid, is colored black, the 3D wide-type residues colored green and mutant ones colored red, whereas the protein is colored cyan.

![The 3D structure of the CEBPA protein model was generated by using RaptorX; it could not generate the 3D structure of all amino acid positions; therefore, the model was done from positions 52 to 358, due to the lack of information. 3D indicates 3-dimensional.](10.1177_1176935119870817-fig6){#fig6-1176935119870817}

![D63N: aspartate (green box) changes to asparagine (red box) at position 63.](10.1177_1176935119870817-fig7){#fig7-1176935119870817}

![R288P: the amino acid arginine changes to proline at position 288; illustration was done by UCSF Chimera (v 1.8.) and project HOPE.](10.1177_1176935119870817-fig8){#fig8-1176935119870817}

![N292S: the amino acid asparagine changes to serine at position 292; illustration was done by UCSF Chimera (v 1.8.) and project HOPE.](10.1177_1176935119870817-fig9){#fig9-1176935119870817}

![N292T: the amino acid asparagine changes to threonine at position 292; illustration was done by UCSF Chimera (v 1.8.) and project HOPE.](10.1177_1176935119870817-fig10){#fig10-1176935119870817}

![R339W: the amino acid arginine changes to tryptophan at position 339; illustration was done by UCSF Chimera (v 1.8.) and project HOPE.](10.1177_1176935119870817-fig11){#fig11-1176935119870817}

In [Figure 7](#fig7-1176935119870817){ref-type="fig"}, D63N shows the native amino acid (aspartic acid) and the mutant one (asparagine) at position 63; the mutated residue is located on the surface of a domain with unknown function; the residue was not found to be in contact with other domains of which the function is known within the used structure; however, contact with other molecules or domains is still possible and might be affected by this mutation.

In [Figure 8](#fig8-1176935119870817){ref-type="fig"}, R288P shows close-up angle of the native amino acid (arginine) and the mutant one (proline) at position 288; the mutated residue is located in a domain that is important for the activity of the protein and in contact with residues in another domain, and it is possible that this interaction is important for the correct function of the protein. The mutation can affect this interaction and as such affect protein function; the mutation introduces an amino acid with different properties, which can disturb this domain and abolish its function, the charge of the wild-type residue is lost by this mutation, which can cause loss of interactions with other molecules; the mutant residue is smaller than the wild-type residue; and this will cause a possible loss of external interactions.

In [Figure 9](#fig9-1176935119870817){ref-type="fig"}, N292S shows the schematic structures of the original amino acid (asparagine) and the mutant one (serine) at position 292; each amino acid has its own specific size, charge, and hydrophobicity value. The original wild-type residue and newly introduced mutant residue often differ in these properties; the mutant residue is more hydrophobic than the wild-type residue; the mutant residue is smaller than the wild-type residue; and this will cause a possible loss of external interactions.

In [Figure 10](#fig10-1176935119870817){ref-type="fig"}, N292T shows close-up angle of the native amino acid (asparagine) and the mutant one (threonine) at position 292; the mutated residue is located in a domain that is important for the activity of the protein and in contact with residues in another domain. It is possible that this interaction is important for the correct function of the protein. The mutation can affect this interaction and as such affect protein function; the mutant residue is smaller than the wild-type residue; and this will cause a possible loss of external interactions.

In [Figure 11](#fig11-1176935119870817){ref-type="fig"}, R339W shows the schematic structures of the original amino acid (arginine) and the mutant one (tryptophan) at position 339; the residue is located on the surface of the protein; mutation of this residue can disturb interactions with other molecules or other parts of the protein; and the charge of the wild-type residue (positive) is lost by this mutation. This can cause loss of interactions with other molecules. The mutant residue is more hydrophobic than the wild-type residue, which can disturb this domain and abolish its function.

We also used ConSurf web server; the nsSNPs that are shown by black boxes located in highly conserved regions and predicted to cause structural and functional impacts on CEBPA protein ([Figure 12](#fig12-1176935119870817){ref-type="fig"}).

![The conserved amino acids across species in CEBPA protein were determined using ConSurf. e: exposed residues according to the neural-network algorithm are indicated in orange letters. b: residues predicted to be buried are demonstrated via green letters. f: predicted functional residues (highly conserved and exposed) are indicated with red letters. s: predicted structural residues (highly conserved and buried) are demonstrated in blue letters. I: insufficient data---the calculation for this site performed in less than 10% of the sequences is demonstrated in yellow letters.](10.1177_1176935119870817-fig12){#fig12-1176935119870817}

GeneMANIA revealed strong functional associations that *CEBPA* gene had observed with transforming growth factor beta (*TGFB1*) and tumor necrosis factor (*TNF*) genes ([Figure 13](#fig13-1176935119870817){ref-type="fig"}). Besides, weak interactions with less confidence have been observed for prolactin regulatory element binding (*PREB*) and early B cell factor 1 (*EBF1*) genes. The genes co-expressed with, sharing similar protein domain, or contributed to achieve similar function are shown in [Tables 4](#table4-1176935119870817){ref-type="table"} and [5](#table5-1176935119870817){ref-type="table"}.

![Interaction between *CEBPA* and its related genes.](10.1177_1176935119870817-fig13){#fig13-1176935119870817}

###### 

The *CEBPA* gene functions and its appearance in network and genome.

![](10.1177_1176935119870817-table4)

  Function                                          FDR           Genes in network   Genes in genome
  ------------------------------------------------- ------------- ------------------ -----------------
  Regulation of multiorganism process               0.375211393   4                  216
  Response to bacterium                             0.375211393   4                  167
  Golgi lumen                                       0.375211393   3                  84
  Viral genome replication                          0.375211393   3                  64
  Negative regulation of multiorganism process      0.375211393   3                  79
  Negative regulation of cytokine production        0.698836286   3                  111
  Negative regulation of fat cell differentiation   0.698836286   2                  22
  Regulation of viral process                       0.828689471   3                  134
  Protein import into nucleus, translocation        0.828689471   2                  26
  Lipopolysaccharide-mediated signaling pathway     0.829247433   2                  30

Abbreviation: FDR, false discovery rate.

FDR is greater than or equal to the probability that this is a false positive.

###### 

The gene co-expression, shared domain, and interaction with CEBPA gene network.

![](10.1177_1176935119870817-table5)

  Gene 1      Gene 2      Weight       Network group
  ----------- ----------- ------------ -----------------------
  *TK1*       *PCBP2*     0.00530806   Co-expression
  *RUNX1T1*   *SLC2A4*    0.02216304   Co-expression
  *TRIM26*    *CEBPA*     0.01914615   Co-expression
  *TOP2A*     *TK1*       0.00946418   Co-expression
  *AFP*       *CEBPA*     0.01361087   Co-expression
  *TK1*       *AFP*       0.02290919   Co-expression
  *MMP11*     *CEBPA*     0.00309695   Co-expression
  *AFP*       *ADH7*      0.00763638   Co-expression
  *TK1*       *FDPS*      0.00380695   Co-expression
  *TOP2A*     *TK1*       0.00417671   Co-expression
  *TOP2A*     *TK1*       0.004765     Co-expression
  *TOP2A*     *TK1*       0.00795774   Co-expression
  *TOP2A*     *UHRF1*     0.00966428   Co-expression
  *TOP2A*     *TK1*       0.00797961   Co-expression
  *MMP11*     *CEBPA*     0.00799819   Co-expression
  *TOP2A*     *TK1*       0.00777507   Co-expression
  *TK1*       *UHRF1*     0.01041377   Co-expression
  *TOP2A*     *UHRF1*     0.01174308   Co-expression
  *LYZ*       *PCBP2*     0.01229207   Co-expression
  *AFP*       *LYZ*       0.0059269    Co-expression
  *AFP*       *ONECUT1*   0.01915715   Co-expression
  *PREB*      *TRIM26*    0.00768956   Co-expression
  *TRIM26*    *FDPS*      0.01174667   Co-expression
  *RUNX1T1*   *EBF1*      0.00970602   Co-expression
  *TK1*       *UHRF1*     0.00909379   Co-expression
  *TOP2A*     *UHRF1*     0.01288607   Co-expression
  *TOP2A*     *TK1*       0.00770565   Co-expression
  *FDPS*      *TNF*       0.00918617   Co-localization
  *TOP2A*     *TGFB1*     0.00832004   Co-localization
  *TOP2A*     *FDPS*      0.0065701    Co-localization
  *TOP2A*     *TK1*       0.00696822   Co-localization
  *NCOA3*     *CEBPA*     0.29423913   Genetic interactions
  *TGFB1*     *CEBPA*     0.00700947   Pathway
  *DEFA3*     *CEBPA*     0.17928578   Pathway
  *UHRF1*     *CEBPA*     0.17928578   Pathway
  *MMP11*     *CEBPA*     0.17928578   Pathway
  *UBP1*      *CEBPA*     0.17928578   Pathway
  *ADH7*      *CEBPA*     0.17928578   Pathway
  *FDPS*      *CEBPA*     0.17928578   Pathway
  *TRIM26*    *CEBPA*     0.07640404   Pathway
  *AFP*       *CEBPA*     0.07640404   Pathway
  *PREB*      *CEBPA*     0.07618967   Pathway
  *TK1*       *CEBPA*     0.07600352   Pathway
  *TOP2A*     *CEBPA*     0.07955996   Pathway
  *RUNX1T1*   *CEBPA*     0.07140907   Pathway
  *TGFB1*     *CEBPA*     0.3443214    Pathway
  *TNF*       *CEBPA*     0.3443214    Pathway
  *NCOA3*     *CEBPA*     0.01949818   Pathway
  *SLC2A4*    *CEBPA*     0.10226673   Pathway
  *EBF1*      *CEBPA*     0.08983881   Pathway
  *LYZ*       *CEBPA*     0.3277232    Pathway
  *TOP2A*     *UHRF1*     0.02391628   Physical interactions
  *ONECUT1*   *CEBPA*     1            Physical interactions
  *PCBP2*     *CEBPA*     0.6985996    Physical interactions

The VEP annotates variants using a wide range of reference data, including transcripts, regulatory regions, and frequencies from previously observed variants, citations, clinical significance information, and predictions of biophysical consequences of variants, and that is what makes VEP to give accurate results; as far as we know, the only limitation is that VEP annotates each input variant independently, without considering the potential compound effects of combining alternate alleles across multiple variant loci,^[@bibr68-1176935119870817]^ and this is the reason why we could not predict the consequences of N292S mutation, whereas the predicted variant consequences are shown in [Table 6](#table6-1176935119870817){ref-type="table"}. VEP reported regulatory consequences for many variants, including 5 variants within a coding region, 6 variants within a non-coding region, 10 variants within upstream gene, 6 variants within downstream gene, 4 variants within non-coding transcript exon, and 1 variant within transcription factor binding site (TFBS); in conclusion, mutations within a coding region affect the protein function, whereas regulatory variants within non-coding genomic regions can greatly affect disease and could be involved in the specific recruitment or sequestration of spliceosome factors and RNA-binding proteins (RBPs)^[@bibr74-1176935119870817],[@bibr75-1176935119870817]^; the SNPs in the upstream, downstream, 5′-, and 3′-UTRs might affect transcription or translation process^[@bibr76-1176935119870817]^; whereas alteration at TFBS has many consequences, such as variants within a TFBS differentially influence its TF-binding affinity; another consequence that could affect TFBS is that multiple variants in the promoter regions can "transform" an existing binding site of a particular TF into a site for another TF, even from a different TF family.^[@bibr77-1176935119870817]^ [Figure 14](#fig14-1176935119870817){ref-type="fig"} illustrates the summary pie charts and statistics.

###### 

Shows variant consequences, transcripts, and regulatory features by VEP tool.

![](10.1177_1176935119870817-table6)

  Uploaded variation   Location               Allele   Consequence                          SYMBOL       Gene              Feature             Protein position   Amino acids
  -------------------- ---------------------- -------- ------------------------------------ ------------ ----------------- ------------------- ------------------ -------------
  rs1455027551         19:33301400-33301400   A        Missense variant                     CEBPA        ENSG00000245848   ENST00000498907.3   339                R/W
  --                   --                     A        Non-coding transcript exon variant   AC008738.5   ENSG00000267727   ENST00000587312.1   --                 --
  --                   --                     A        Downstream gene variant              AC008738.3   ENSG00000267580   ENST00000589932.1   --                 --
  --                   --                     A        Upstream gene variant                CEBPA-DT     ENSG00000267296   ENST00000592982.2   --                 --
  --                   --                     A        Upstream gene variant                AC008738.2   ENSG00000267130   ENST00000593041.1   --                 --
  --                   --                     A        Regulatory region variant            --           --                ENSR00000588478     --                 --
  rs776590829          19:33301540-33301540   C        Missense variant                     CEBPA        ENSG00000245848   ENST00000498907.3   292                N/S
  --                   --                     G        missense variant                     CEBPA        ENSG00000245848   ENST00000498907.3   292                N/T
  --                   --                     C        Non-coding transcript exon variant   AC008738.5   ENSG00000267727   ENST00000587312.1   --                 --
  --                   --                     G        Non-coding transcript exon variant   AC008738.5   ENSG00000267727   ENST00000587312.1   --                 --
  --                   --                     C        Downstream gene variant              AC008738.3   ENSG00000267580   ENST00000589932.1   --                 --
  --                   --                     G        Downstream gene variant              AC008738.3   ENSG00000267580   ENST00000589932.1   --                 --
  --                   --                     C        Upstream gene variant                CEBPA-DT     ENSG00000267296   ENST00000592982.2   --                 --
  --                   --                     G        Upstream gene variant                CEBPA-DT     ENSG00000267296   ENST00000592982.2   --                 --
  --                   --                     C        Upstream gene variant                AC008738.2   ENSG00000267130   ENST00000593041.1   --                 --
  --                   --                     G        Upstream gene variant                AC008738.2   ENSG00000267130   ENST00000593041.1   --                 --
  --                   --                     C        Regulatory region variant            --           --                ENSR00000588478     --                 --
  --                   --                     G        Regulatory region variant            --           --                ENSR00000588478     --                 --
  rs1064794962         19:33301552-33301552   G        Missense variant                     CEBPA        ENSG00000245848   ENST00000498907.3   288                R/P
  --                   --                     G        Non-coding transcript exon variant   AC008738.5   ENSG00000267727   ENST00000587312.1   --                 --
  --                   --                     G        Downstream gene variant              AC008738.3   ENSG00000267580   ENST00000589932.1   --                 --
  --                   --                     G        Upstream gene variant                CEBPA-DT     ENSG00000267296   ENST00000592982.2   --                 --
  --                   --                     G        Upstream gene variant                AC008738.2   ENSG00000267130   ENST00000593041.1   --                 --
  --                   --                     G        Regulatory region variant            --           --                ENSR00000588478     --                 --
  rs1452063514         19:33302228-33302228   T        Missense variant                     CEBPA        ENSG00000245848   ENST00000498907.3   63                 D/N
  --                   --                     T        Downstream gene variant              AC008738.5   ENSG00000267727   ENST00000587312.1   --                 --
  --                   --                     T        Downstream gene variant              AC008738.3   ENSG00000267580   ENST00000589932.1   --                 --
  --                   --                     T        Upstream gene variant                CEBPA-DT     ENSG00000267296   ENST00000592982.2   --                 --
  --                   --                     T        Upstream gene variant                AC008738.2   ENSG00000267130   ENST00000593041.1   --                 --
  --                   --                     T        Regulatory region variant            --           --                ENSR00000588478     --                 --
  --                   --                     T        Regulatory region variant            --           --                ENSR00000588491     --                 --
  --                   --                     T        TF binding site variant              --           --                ENSM00524410754     --                 --

Abbreviations: TF, transcription factor; VEP, Variant Effect Predictor.

![Summary pie charts and statistics.](10.1177_1176935119870817-fig14){#fig14-1176935119870817}

Single nucleotide polymorphisms in 3′-UTR of *CEBPA* gene were submitted as batch to PolymiRTS server. The result showed that 11 SNPs may affect microRNA binding sites. As an example, rs2376497 SNP containing (D) allele had 8 microRNA sites (miRSite) as target binding site that can disrupt a conserved miRNA and (C) alleles had 5 miRSites that disrupt a conserved miRSite. [Table 7](#table7-1176935119870817){ref-type="table"} demonstrates the SNPs predicted by PolymiRTS to induce disruption or formation of miRSite.

###### 

SNPs and INDELs in miRNA target sites in *CEBPA* gene.

![](10.1177_1176935119870817-table7)

  Location   dbSNP ID      miR ID             Conservation   miRSite         Function class   Context + score change
  ---------- ------------- ------------------ -------------- --------------- ---------------- ------------------------
  33791117   rs116528776   hsa-miR-548aa      6              tcctttTGGTTTT   D                −0.032
                           hsa-miR-548ap-3p   6              tcctttTGGTTTT   D                −0.032
                           hsa-miR-548t-3p    6              tcctttTGGTTTT   D                −0.032
                           hsa-miR-186-3p     9              tcCTTTGGGtttt   C                −0.11
                           hsa-miR-548as-3p   6              tcctttGGGTTTT   C                −0.079
  33791158   rs113670631   hsa-miR-5192       7              ACTCTCCgtcggc   D                −0.103
                           hsa-miR-5739       7              aCTCTCCGtcggc   D                −0.234
  33791211   rs34017519    hsa-miR-548aa      15             tttattTGGTTTT   D                −0.12
                           hsa-miR-548ap-3p   15             tttattTGGTTTT   D                −0.12
                           hsa-miR-548t-3p    15             tttattTGGTTTT   D                −0.12
                           hsa-miR-548at-3p   15             tttattCGGTTTT   C                −0.179
                           hsa-miR-548ay-3p   15             tttattCGGTTTT   C                −0.169
  33791239   rs146104564   hsa-miR-3939       21             aatgTGCGCGTct   D                −0.344
  33791250   rs187516157   hsa-miR-130a-5p    11             tgtgcAATGTGAA   D                −0.06
                           hsa-miR-23a-3p     11             tgtgcAATGTGAA   D                −0.06
                           hsa-miR-23b-3p     11             tgtgcAATGTGAA   D                −0.06
                           hsa-miR-23c        11             tgtgcAATGTGAA   D                −0.039
                           hsa-miR-25-3p      12             tGTGCAATgtgaa   D                −0.092
                           hsa-miR-32-5p      12             tGTGCAATgtgaa   D                −0.102
                           hsa-miR-363-3p     12             tGTGCAATgtgaa   D                −0.092
                           hsa-miR-367-3p     12             tGTGCAATgtgaa   D                −0.111
                           hsa-miR-92a-3p     12             tGTGCAATgtgaa   D                −0.083
                           hsa-miR-92b-3p     12             tGTGCAATgtgaa   D                −0.074
                           hsa-miR-513b-5p    15             tgtgcaTTGTGAA   C                0.006
  33791649   rs2376497     hsa-miR-1233-5p    4              acgcctCTCCCAC   D                −0.082
                           hsa-miR-30c-1-3p   4              acgccTCTCCCAc   D                0.01
                           hsa-miR-30c-2-3p   4              acgccTCTCCCAc   D                0.01
                           hsa-miR-6731-5p    3              acgcCTCTCCCAc   D                −0.143
                           hsa-miR-6778-5p    4              acgcctCTCCCAC   D                −0.101
                           hsa-miR-6788-5p    4              acgccTCTCCCAc   D                −0.018
                           hsa-miR-6878-5p    4              acgccTCTCCCAc   D                −0.04
                           hsa-miR-8085       3              acgcCTCTCCCAc   D                −0.143
                           hsa-miR-3153       3              acgcCTTTCCCAc   C                −0.046
                           hsa-miR-4484       2              aCGCCTTTcccac   C                −0.073
                           hsa-miR-4668-5p    4              acgccTTTCCCAc   C                0.033
                           hsa-miR-6733-5p    3              acgcCTTTCCCAc   C                −0.067
                           hsa-miR-6739-5p    3              acgcCTTTCCCAc   C                −0.078
  33791665   rs192371350                                                                      
                           hsa-miR-6508-5p    21             gagggTTTCTAGt   C                0.048
                           hsa-miR-8067       21             gagggTTTCTAGt   C                0.058
  33791807   rs1049969     hsa-miR-1233-3p    2              aggaggAGGGCTC   D                −0.167
                           hsa-miR-4290       2              aggaGGAGGGCtc   D                −0.177
                           hsa-miR-4667-3p    2              aggAGGAGGGctc   D                −0.035
                           hsa-miR-4687-5p    2              aggagGAGGGCTc   D                −0.12
                           hsa-miR-5193       2              agGAGGAGGgctc   D                −0.083
                           hsa-miR-660-3p     9              AGGAGGAgggctc   D                −0.143
                           hsa-miR-1225-3p    2              aggaggGGGGCTC   C                −0.204
                           hsa-miR-3943       2              aggagGGGGGCTc   C                −0.163
                           hsa-miR-6887-3p    3              aGGAGGGGggctc   C                −0.117
  33791883   rs41367646    hsa-miR-519d-5p    9              taTTTGGAGgttt   D                −0.115
                           hsa-miR-3671       7              TATTTGAAggttt   C                −0.051
                           hsa-miR-607        9              tATTTGAAggttt   C                0.016
  33792082   rs184965384   hsa-miR-2467-3p    4              cccttCCTCTGCg   D                −0.162
                           hsa-miR-3125       6              cccTTCCTCTgcg   D                −0.003
                           hsa-miR-3202       4              CCCTTCCtctgcg   D                −0.13
                           hsa-miR-3916       6              cccTTCCTCTgcg   D                0.016
                           hsa-miR-4476       7              cCCTTCCTctgcg   D                −0.096
                           hsa-miR-6847-5p    6              ccctTCCTCTGcg   D                −0.109
                           hsa-miR-6859-5p    6              cccTTCCTCTgcg   D                0.006
                           hsa-miR-6876-5p    7              cCCTTCCTctgcg   D                −0.059
                           hsa-miR-298        4              cccttCTTCTGCg   C                −0.146
                           hsa-miR-3154       4              CCCTTCTtctgcg   C                −0.131
                           hsa-miR-3185       5              ccCTTCTTCtgcg   C                0.017
  33792099   rs187751931   hsa-miR-3186-3p    7              tgctCCGCGTGtc   D                −0.314
                           hsa-miR-151a-5p    7              tgCTCCTCGtgtc   C                −0.204
                           hsa-miR-151b       7              tgCTCCTCGtgtc   C                −0.204

Abbreviations: miRSite, microRNA site; SNPs, single nucleotide polymorphisms.

D: the derived allele disrupts a conserved miRNA site (ancestral allele with support ⩾ 2). C: the derived allele creates a new miRNA site.

The limitations of this study are that it focuses on coding and 3′-UTRs using different numbers of tools of silico analysis; yet there are number of genes responsible for AML although AML is frequently triggered by mutation in *CEBPA* gene^[@bibr10-1176935119870817][@bibr11-1176935119870817][@bibr12-1176935119870817]-[@bibr13-1176935119870817]^; in general, it is likely to achieve that computational approach remains as an accurate way to make a rapid analysis regarding the expected effect of mutations; nevertheless, the more factors that are taken into account, the more accurate the prediction will be. To take the best advantage of bioinformatics analysis, different computational tools could be used, trying to cover the major aspects influencing protein structure and function, Mutation Taster,^[@bibr78-1176935119870817]^ SNPdryad,^[@bibr79-1176935119870817]^ and ACES (a machine learning toolbox for clustering analysis and visualization).^[@bibr80-1176935119870817]^ The 5′-UTRs have not been analyzed in this study; these SNPs are likely to affect the level of gene expression; the impact of SNPs at the 5′-UTRs can be predicted by using some of the RNA assessment tools, such as PreTIS.^[@bibr81-1176935119870817]^

This study is the first in silico analysis while all other previous studies were next-generation sequencing (NGS) analysis, in vitro analysis, and in vivo analysis^[@bibr14-1176935119870817],[@bibr71-1176935119870817],[@bibr82-1176935119870817],[@bibr83-1176935119870817]^; also, it is the first computational analysis, which revealed that 5 SNPs were identified as highly deleterious in the coding region, whereas 11 SNPs were detected to be damaging in the 3′-UTR, and therefore, may be used as diagnostic markers for AML and might create an ideal target for cancer therapy. These outcomes in combination with all earlier discoveries make AML a model for understanding the philosophies of cancer development.^[@bibr84-1176935119870817],[@bibr85-1176935119870817]^ Finally, clinical techniques are recommended to support these findings.

Conclusions {#section33-1176935119870817}
===========

In this study, the impact of functional mutations in the CEBPA gene was investigated through different bioinformatics analysis techniques, which determined that R339W, R288P, N292S, N292T, and D63N are pathogenic mutations, which have a possible functional influence, and therefore, can be used as diagnostic markers and may assist in genetic studies with a special consideration of the large heterogeneity of AML among different populations. In addition, this study draws attention to 11 SNPs that were identified to be deleterious in the 3′-UTR.
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